MedTrace Logo

AcceXible Speech-Based Screening for Depression and Anxiety in University Students (BUAP, Mexico)

NCT07553130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 785

Last updated 2026-04-27

No results posted yet for this study

Summary

Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD). Emerging evidence suggests that depression affects both the acoustic properties and content of speech, making speech analysis a promising candidate as a digital biomarker for early screening.

This study evaluates the validity of acceXible, a speech-based machine learning platform, for the detection and monitoring of depression and anxiety in the student population of the Benemérita Universidad Autónoma de Puebla (BUAP), Mexico. AcceXible captures spontaneous speech through open-ended interview tasks and applies automated acoustic and linguistic analysis.

The primary objective is to evaluate the validity of the acceXible spontaneous speech analysis system for depression and anxiety screening, assessed against the PHQ and GAD scales as reference standards. Secondary objectives include examining associations between speech-derived variables and other study measures, evaluating participant engagement with digital mental health resources, assessing user satisfaction with the platform, and analyzing longitudinal changes in scores across follow-up assessments.

Conditions

  • Depression - Major Depressive Disorder
  • Anxiety

Interventions

DEVICE

AcceXible

Speech analysis

Sponsors & Collaborators

  • Benemerita Universidad Autónoma de Puebla

    collaborator UNKNOWN

  • Accexible

    lead INDUSTRY

Eligibility

Min Age
16 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-20
Primary Completion
2025-06-06
Completion
2025-06-06

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07553130 on ClinicalTrials.gov